UPDATE: Jefferies Reiterates Buy Rating, Raises PT on ImmunoGen
In a report published Monday, Jefferies reiterated its Buy rating on ImmunoGen (NASDAQ: IMGN ), and slightly raised its price target from $16.00 to $17.00. Jefferies noted, “On its F2Q13 call, IMGN highlighted progress on its earlier stage, internally developed programs including 901, 854, and 529, all of which are
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here